#ExistInterpData>The vircoTYPE HIV-1 software is used in conjunction with HIV-1 sequencing to calculate drug resistance and susceptibility as an aid in the monitoring and treatment of HIV infection. The protease and codons 1-335 of the reverse transcriptase genes are sequenced at ARUP Laboratories, and the sequence is sent to Janssen Diagnostics (www.janssendiagnostics.com) for analysis using its bioinformatics engine. The vircoTYPE HIV-1 Report should be used in conjunction with clinical presentation and other laboratory markers. Response to therapy depends on multiple factors, including percentage of the resistant virus population, dosing and pharmacokinetics, and patient compliance. Resistance interpretations obtained through different test methods should not be used interchangeably.
HIV sequencing is performed using the Abbott Molecular Viroseq HIV-1 Genotyping system. Some insertions or deletions may be difficult to detect with the instrument software. This test may not detect minor HIV-1 populations less than 20 percent of the total population.
The performance characteristics of this test were determined by ARUP Laboratories, Inc.
See Compliance Statement B: www.aruplab.com/CS
||This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 1,000 HIV-1 RNA copies per mL of plasma.
For a complete list of drugs currently profiled by this assay, please contact ARUP Client Services.
||HIV Drug Resistance (Human Immunodeficiency Virus 1, virco®TYPE)
, HIV Genotype (Human Immunodeficiency Virus 1, virco®TYPE)